Possible role of glutathione in predicting radiotherapy response of cervix cancer

Ganesh Krishna R. Jadhav, Pullara Bhanumathi, Pathirissery Uma Devi, Tattikonda Seetharamaiah, Mamudipudi S. Vidyasagar, Kilari Koteshwer Rao, Chandrashekhar S. Hospet, Johnson Gilbert R. Solomon

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Purpose: To see if changes in tumor/blood glutathione (GSH) levels after one fraction of radiotherapy can be correlated with the treatment response in patients with carcinoma of the uterine cervix. Methods and Materials: The study was done on 45 patients with squamous cell carcinoma of the uterine cervix, FIGO Stages IIB (17 patients) and IIIB (28 patients). Stage IIB patients received 35 Gy of cobalt-60 external radiotherapy (RT) in 16 fractions over 4 weeks with a concurrent high-dose-rate intracavitary dose of 8.5 Gy to point A once a week. Stage IIIB patients were given 45 Gy of RT in 20 fractions over 5 weeks, followed by two doses of intracavitary therapy once a week. Blood and tumor samples were collected before and after one dose of RT and GSH was estimated. Tumor response was assessed clinically at 1 month after treatment. Results: Glutathione levels in both blood and tumor showed a significant decrease after one fraction of RT, but the degree of decrease varied among patients. There was a good correlation between the extent of GSH decrease and the tumor response. All patients who had complete response (CR) (seven Stage IIB and eight Stage IIIB) showed ≤70% decrease in both tumor and blood GSH, while those who had <50% regression (NR) (five Stage IIB and 13 Stage IIIB) showed <50% decrease in GSH. The partial responders recorded an intermediate level (50-70%) of depletion in blood and tumor GSH. Conclusions: The results indicate that the changes in tumor/blood GSH levels after one fraction of RT could serve as an index of tumor response to therapy and may help in identifying radioresistant tumors, at least in the case of cervix carcinoma.

Original languageEnglish
Pages (from-to)3-5
Number of pages3
JournalInternational Journal of Radiation Oncology Biology Physics
Volume41
Issue number1
DOIs
Publication statusPublished - 01-04-1998

Fingerprint

glutathione
Uterine Cervical Neoplasms
Glutathione
radiation therapy
Radiotherapy
tumors
cancer
blood
Neoplasms
Cervix Uteri
dosage
therapy
Carcinoma
cobalt 60
transponders
Therapeutics
Cobalt
regression analysis
Squamous Cell Carcinoma
depletion

All Science Journal Classification (ASJC) codes

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Jadhav, Ganesh Krishna R. ; Bhanumathi, Pullara ; Devi, Pathirissery Uma ; Seetharamaiah, Tattikonda ; Vidyasagar, Mamudipudi S. ; Rao, Kilari Koteshwer ; Hospet, Chandrashekhar S. ; Solomon, Johnson Gilbert R. / Possible role of glutathione in predicting radiotherapy response of cervix cancer. In: International Journal of Radiation Oncology Biology Physics. 1998 ; Vol. 41, No. 1. pp. 3-5.
@article{b89e4cc5c1ed4603a645e5651d4b2073,
title = "Possible role of glutathione in predicting radiotherapy response of cervix cancer",
abstract = "Purpose: To see if changes in tumor/blood glutathione (GSH) levels after one fraction of radiotherapy can be correlated with the treatment response in patients with carcinoma of the uterine cervix. Methods and Materials: The study was done on 45 patients with squamous cell carcinoma of the uterine cervix, FIGO Stages IIB (17 patients) and IIIB (28 patients). Stage IIB patients received 35 Gy of cobalt-60 external radiotherapy (RT) in 16 fractions over 4 weeks with a concurrent high-dose-rate intracavitary dose of 8.5 Gy to point A once a week. Stage IIIB patients were given 45 Gy of RT in 20 fractions over 5 weeks, followed by two doses of intracavitary therapy once a week. Blood and tumor samples were collected before and after one dose of RT and GSH was estimated. Tumor response was assessed clinically at 1 month after treatment. Results: Glutathione levels in both blood and tumor showed a significant decrease after one fraction of RT, but the degree of decrease varied among patients. There was a good correlation between the extent of GSH decrease and the tumor response. All patients who had complete response (CR) (seven Stage IIB and eight Stage IIIB) showed ≤70{\%} decrease in both tumor and blood GSH, while those who had <50{\%} regression (NR) (five Stage IIB and 13 Stage IIIB) showed <50{\%} decrease in GSH. The partial responders recorded an intermediate level (50-70{\%}) of depletion in blood and tumor GSH. Conclusions: The results indicate that the changes in tumor/blood GSH levels after one fraction of RT could serve as an index of tumor response to therapy and may help in identifying radioresistant tumors, at least in the case of cervix carcinoma.",
author = "Jadhav, {Ganesh Krishna R.} and Pullara Bhanumathi and Devi, {Pathirissery Uma} and Tattikonda Seetharamaiah and Vidyasagar, {Mamudipudi S.} and Rao, {Kilari Koteshwer} and Hospet, {Chandrashekhar S.} and Solomon, {Johnson Gilbert R.}",
year = "1998",
month = "4",
day = "1",
doi = "10.1016/S0360-3016(98)00017-0",
language = "English",
volume = "41",
pages = "3--5",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

Possible role of glutathione in predicting radiotherapy response of cervix cancer. / Jadhav, Ganesh Krishna R.; Bhanumathi, Pullara; Devi, Pathirissery Uma; Seetharamaiah, Tattikonda; Vidyasagar, Mamudipudi S.; Rao, Kilari Koteshwer; Hospet, Chandrashekhar S.; Solomon, Johnson Gilbert R.

In: International Journal of Radiation Oncology Biology Physics, Vol. 41, No. 1, 01.04.1998, p. 3-5.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Possible role of glutathione in predicting radiotherapy response of cervix cancer

AU - Jadhav, Ganesh Krishna R.

AU - Bhanumathi, Pullara

AU - Devi, Pathirissery Uma

AU - Seetharamaiah, Tattikonda

AU - Vidyasagar, Mamudipudi S.

AU - Rao, Kilari Koteshwer

AU - Hospet, Chandrashekhar S.

AU - Solomon, Johnson Gilbert R.

PY - 1998/4/1

Y1 - 1998/4/1

N2 - Purpose: To see if changes in tumor/blood glutathione (GSH) levels after one fraction of radiotherapy can be correlated with the treatment response in patients with carcinoma of the uterine cervix. Methods and Materials: The study was done on 45 patients with squamous cell carcinoma of the uterine cervix, FIGO Stages IIB (17 patients) and IIIB (28 patients). Stage IIB patients received 35 Gy of cobalt-60 external radiotherapy (RT) in 16 fractions over 4 weeks with a concurrent high-dose-rate intracavitary dose of 8.5 Gy to point A once a week. Stage IIIB patients were given 45 Gy of RT in 20 fractions over 5 weeks, followed by two doses of intracavitary therapy once a week. Blood and tumor samples were collected before and after one dose of RT and GSH was estimated. Tumor response was assessed clinically at 1 month after treatment. Results: Glutathione levels in both blood and tumor showed a significant decrease after one fraction of RT, but the degree of decrease varied among patients. There was a good correlation between the extent of GSH decrease and the tumor response. All patients who had complete response (CR) (seven Stage IIB and eight Stage IIIB) showed ≤70% decrease in both tumor and blood GSH, while those who had <50% regression (NR) (five Stage IIB and 13 Stage IIIB) showed <50% decrease in GSH. The partial responders recorded an intermediate level (50-70%) of depletion in blood and tumor GSH. Conclusions: The results indicate that the changes in tumor/blood GSH levels after one fraction of RT could serve as an index of tumor response to therapy and may help in identifying radioresistant tumors, at least in the case of cervix carcinoma.

AB - Purpose: To see if changes in tumor/blood glutathione (GSH) levels after one fraction of radiotherapy can be correlated with the treatment response in patients with carcinoma of the uterine cervix. Methods and Materials: The study was done on 45 patients with squamous cell carcinoma of the uterine cervix, FIGO Stages IIB (17 patients) and IIIB (28 patients). Stage IIB patients received 35 Gy of cobalt-60 external radiotherapy (RT) in 16 fractions over 4 weeks with a concurrent high-dose-rate intracavitary dose of 8.5 Gy to point A once a week. Stage IIIB patients were given 45 Gy of RT in 20 fractions over 5 weeks, followed by two doses of intracavitary therapy once a week. Blood and tumor samples were collected before and after one dose of RT and GSH was estimated. Tumor response was assessed clinically at 1 month after treatment. Results: Glutathione levels in both blood and tumor showed a significant decrease after one fraction of RT, but the degree of decrease varied among patients. There was a good correlation between the extent of GSH decrease and the tumor response. All patients who had complete response (CR) (seven Stage IIB and eight Stage IIIB) showed ≤70% decrease in both tumor and blood GSH, while those who had <50% regression (NR) (five Stage IIB and 13 Stage IIIB) showed <50% decrease in GSH. The partial responders recorded an intermediate level (50-70%) of depletion in blood and tumor GSH. Conclusions: The results indicate that the changes in tumor/blood GSH levels after one fraction of RT could serve as an index of tumor response to therapy and may help in identifying radioresistant tumors, at least in the case of cervix carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0032054644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032054644&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(98)00017-0

DO - 10.1016/S0360-3016(98)00017-0

M3 - Article

VL - 41

SP - 3

EP - 5

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 1

ER -